BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp decreased its holdings in Humana Inc (NYSE:HUM) by 23.6% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 37,673 shares of the insurance provider’s stock after selling 11,665 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp’s holdings in Humana were worth $10,021,000 at the end of the most recent quarter.
A number of other hedge funds have also added to or reduced their stakes in HUM. We Are One Seven LLC acquired a new stake in Humana in the 4th quarter valued at about $31,000. Proficio Capital Partners LLC increased its holdings in shares of Humana by 81.4% during the 4th quarter. Proficio Capital Partners LLC now owns 107 shares of the insurance provider’s stock worth $31,000 after buying an additional 48 shares during the last quarter. Destination Wealth Management increased its holdings in shares of Humana by 130.0% during the 1st quarter. Destination Wealth Management now owns 115 shares of the insurance provider’s stock worth $31,000 after buying an additional 65 shares during the last quarter. Exane Asset Management acquired a new stake in shares of Humana during the 4th quarter worth approximately $43,000. Finally, Sontag Advisory LLC acquired a new stake in shares of Humana during the 4th quarter worth approximately $47,000. Institutional investors own 94.72% of the company’s stock.
NYSE:HUM opened at $260.73 on Thursday. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.65 and a quick ratio of 1.65. The company has a market cap of $33.46 billion, a P/E ratio of 17.92, a P/E/G ratio of 1.02 and a beta of 0.88. Humana Inc has a fifty-two week low of $225.65 and a fifty-two week high of $355.88.
Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, May 1st. The insurance provider reported $4.48 earnings per share for the quarter, topping the Zacks’ consensus estimate of $4.30 by $0.18. The firm had revenue of $16.11 billion during the quarter, compared to analysts’ expectations of $15.67 billion. Humana had a net margin of 2.99% and a return on equity of 20.77%. The firm’s quarterly revenue was up 12.8% on a year-over-year basis. During the same quarter last year, the company posted $3.36 EPS. As a group, equities analysts forecast that Humana Inc will post 17.57 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be given a dividend of $0.55 per share. The ex-dividend date of this dividend is Thursday, June 27th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.84%. Humana’s payout ratio is currently 15.12%.
In related news, insider Christopher H. Hunter sold 15,586 shares of the stock in a transaction that occurred on Monday, February 25th. The shares were sold at an average price of $305.24, for a total transaction of $4,757,470.64. Following the completion of the transaction, the insider now owns 28,100 shares of the company’s stock, valued at approximately $8,577,244. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.54% of the company’s stock.
A number of analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of Humana from a “buy” rating to a “hold” rating in a report on Friday, February 8th. UBS Group assumed coverage on shares of Humana in a report on Tuesday, April 23rd. They set a “neutral” rating and a $266.00 price target for the company. ValuEngine downgraded shares of Humana from a “hold” rating to a “sell” rating in a report on Thursday, April 11th. Credit Suisse Group cut their price target on shares of Humana from $390.00 to $352.00 and set an “outperform” rating for the company in a report on Thursday, February 7th. Finally, Citigroup cut their price target on shares of Humana from $362.00 to $302.00 and set a “buy” rating for the company in a report on Thursday, May 2nd. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and fourteen have given a buy rating to the company. Humana presently has an average rating of “Buy” and an average target price of $337.26.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
See Also: What is the balance sheet?
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.